42 results about "Neural development" patented technology

A method and system for medical imaging of neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD), autism, and schizophrenia. Noninvasive, in vivo methods identify novel brain molecular biomarkers of normal neurodevelopment in order to determine molecular underpinnings of abnormal neurodevelopment. The described brain molecular biomarkers will aid in the presymptomatic diagnosis of neuropsychiatric disorders which begin in childhood and adolescence, such as ADHD, autism, and schizophrenia.

The present invention provides methods of identifying biomarkers indicative of the presence of a neurodevelopmental disorder, including an autism spectrum disorder, in an individual, using cytometry and mass spectrometry. The invention further provides methods of using the identified biomarkers to diagnose the presence of a neurodevelomental disorder, including an autism spectrum disorder.

A milk fat globule membrane-containing infant formula milk powder and a preparation method thereof belong to the technical field of preparation of infant formula milk powder. The milk fat globule membrane-containing infant formula milk powder is composed of essential nutrient components of skim milk powder, concentrated whey protein powder, lactose, demineralized whey powder, vegetable oil, vitamins, mineral substance and the like and meanwhile contains 0.01%-1.5% of milk fat globule membrane (MFGM) extract. By taking breast milk as reference, the nutrient components of the milk fat globule membrane-containing infant formula milk powder, especially the composition of fat globules, can be closer to those of the breast milk and accordingly can promote cerebral and neural development of newborns and improve the cognitive competence as well as anti-infection ability.

The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified.

This invention relates to a method of treating or preventing neuro-degenerative disorders and neuro-developmental disorders by altering the ratio of the amount of full-length TrkB polypeptide to the amount of truncated TrkB polypeptides in a neuron or by altering the ratio of the amount of full-length TrkC polypeptide to the amount of truncated TrkC polypeptides in a neuron.

The instant invention is based, at least in part, on a newly-identified proteasome-independent signaling function of ubiquitinated PSD-95. Mdm2 inhibitors, Mdm4 inhibitors, PSD-95 inhibitors, and/or enantiomers and/or derivatives thereof de-crease endocytosis via preventing PSD-95 ubiquitination, and thereby increase AMPAR, NMDAR, D1 dopamine receptor surface expression in response to a given stimulus (e.g., NMDA, Aβ). Accordingly, the invention provides methods for modulating AM-PARS, NMDARs, or D1 dopamine receptors in a neuronal cell by contacting the neuronal cell with an Mdm2 and/or Mdm4 inhibitor or PSD-95 inhibitor and/or enantiomers and/or derivatives thereof. Mdm2 and/or Mdm4 inhibitors decrease the enzymatic activity of the respective proteins, and/or interactions with their respective substrates. Mdm2 and Mdm4 inhibitors and/or PSD-95 inhibitors of the invention are contemplated for use in the treatment of neurological disorders, neurodevelopmental disorders, and psychiatric disorders. The invention also provides methods to screen for new Mdm2 and Mdm4 inhibitors and PSD-95 inhibitors and/or enantiomers and/or derivatives thereof.

The invention discloses a method for building three-dimensional analog brain development models on the basis of micro-fluidic chips. The method includes main steps of preparing the micro-fluidic chips; forming embryoid bodies (EBs); differentiating and developing analog brains in the micro-fluidic chips. The method has the advantages that the novel engineered three-dimensional analog brain development models can be built by the aid of the method and are micro-reactors with perfusion functions on the basis of micro-fluidic chip technologies; in-vivo brain development basic principles and engineering technologies are combined with one another, and brain early development micro-environments can be effectively simulated; the method is low in cost and reagent dosage and easy to operate, in-situtracking and real-time monitoring can be carried out, animal models and the traditional two-dimensional culture modes can be replaced, brain early development can be simulated to a certain extent, apowerful novel platform can be provided to the aspects such as in-vitro brain development simulation, pathological research on abnormal neural development, medicine screening and toxicity detection, and the like.

The invention provides a composition having effect of relieving symptoms of eczema and a preparation method of the composition. The composition comprises the following raw materials in parts by weightof 1-50 parts of shea butter, 10-50 parts of coconut oil, 10-50 parts of beeswax, 1-10 parts of moringa pterygosperma seed oil, 0.01-5 parts of Lingonberry, 0.01-5 parts of hamamelis leaves, 0.1-5 parts of calendula flowers, 0.1-5 parts of licorice roots and 0.1-5 parts of vitamin E. The composition adopts a full natural formula, is free from medicines or hormones, is free from essential oil andspice which are disadvantageous for neural development of the brains of babies, is nonirritant to skin and good in safety, and can effectively relieve symptoms of skin eczema, itch and swollen.

The invention provides a preparation method of neural stem cells and glutamatergic neurons in cerebral cortex, and relates to an iPSC complete neural induction culture medium. The iPSC complete neuralinduction culture medium comprises the following components: a cell basic culture medium, a cell culture additive, neural development factors and an inhibitor. The invention provides the iPSC complete neural induction culture medium, an iPSC nerve cell culture medium and a culture method. The culture medium includes a serum-free basic medium, a cell additive, neural development factors and an inhibitor. The use of the serum-free basic medium can avoid the introduction of exogenous substances and reduce the risk of pollution. Meanwhile, a variety of nutrients, such as the cell additive and theneural development factors, can enable iPSC cells to be stimulated by signals so that iPSC cells can be activated to promote differentiation. The cell culture method provided by the invention is simple, efficient, low in cost, and can induce high-quality neuron cells in a short period.

The invention relates to a neural stem cell derived tissue engineering spinal cord tissue for simulating a spinal cord tissue structure and main cell constituents. The neural stem cell derived tissue engineering spinal cord tissue is obtained by in-vitro culture and construction through a biological tissue engineering technology and a neural stem cell induced differentiation technology, and has a white matter like structure in the peripheral part and a grey matter like structure in the central part. CNTF (ciliary neurotrophic factor) gene modified oligodendrocyte precursor cells (OPCs) are planted in the white matter like structure; and NT-3 gene and receptor thereof TrkC gene modified neural stem cells (NSCs) are planted in the grey matter like structure. When being transplanted to a spinal cord complete transection injury site, the tissue engineering spinal cord tissue has favorable cell activity and can secrete neurotrophic factors to accelerate regeneration of spinal cord injured central neuron axons; and the tissue engineering spinal cord tissue can realize corresponding functions of oligodendrocytes and neurons, and serves as a neural information transfer relay to form a synaptic connection with regenerated nerve fibers so as to repair spinal cord injured neural circuits. The tissue engineering spinal cord tissue can also be used as an in-vitro model for neural pharmacology and neural development researches.

Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.

The invention belongs to the technical field of biology, and relates to a hippocampal biomarker for a schizophrenia neurodevelopment mouse model, a detection method and a kit. The invention provides the hippocampal biomarker circRNA2 for the schizophrenia neurodevelopment mouse model, the detection method of the marker and the kit for the content of the marker. The invention further provides a biomarker circRNA2 for the hippocampus intervention of the schizophrenia neurodevelopment mouse model and a detection method and kit of the marker. The invention also provides a circRNA-signal pathway-target gene network map of the circRNA2 and a GO/KEGG enrichment analysis result of differential circRNA2 in the hippocampus. The hippocampal biomarker, the detection method and the kit have the advantages that the sample model is established to prove that schizophrenia can be caused to mice due to pregnancy neurological injuries and post-natal stress stimulation; it is discovered for the first timethat the hippocampal circRNA of the mice has difference in expression level, and the change can be reversed by olanzapine intervention. Great significance is provided for studying a relationship between the onset of schizophrenia and epigenetics and searching for new drugs for schizophrenia.

The invention belongs to the technical field of biology, and relates to a hippocampal biomarker for a schizophrenia neurodevelopment mouse model, a detection method and a kit. The invention provides:1) the hippocampal biomarker for a neurodevelopmental mouse model of schizophrenia, which is mRNA1, mRNA2, mRNA5, mRNA10, the detection method for the above-mentioned marker, and the detection kit; 2)the biomarker for hippocampal intervention of the schizophrenia neurodevelopment mouse model, which is mRNA10, the detection method for the above marker, and the detection kit; and 3) mRNA10 mRNA signaling pathway-target gene network map and GO/KEGG enrichment analysis results. The beneficial effects of the present invention are that the schizophrenia neurodevelopment mouse model and the biomarker of intervention are provided for the first time, and the hippocampal mRNA has the difference in expression level. The change can be reversed by olanzapine intervention, which has implications for revealing the pathogenesis of schizophrenia and the therapeutic targets of schizophrenia.

The present invention provides methods of identifying markers indicative of the risk of developing a neurodevelopmental disorder caused in part by antibody- or autoantibody-mediated damage of neural tissue, including autism spectrum disorder (ASD). The invention further provides methods of diagnosing whether an individual has a neurodevelopmental disorder, including an ASD, and methods for determining the risk that a mother's future offspring will develop an a neurodevelopmental disorder, including an ASD.

The present invention provides for the first time the identification of fetal neural exosomal biomarkers isolated from maternal plasma useful in diagnosing fetal neurodevelopmental outcomes. The invention also provides the identification of neonatal neural exosomal biomarkers isolated from neonatal plasma useful in diagnosing neonatal neurodevelopmental outcomes The present invention therefore provides methods, kits and systems for diagnosing fetal neurodevelopmental outcomes, by examining relevant proteins and RNA in fetal neural exosomes isolated from a maternal plasma and neonatal neural exosomes isolated from neonatal plasma.